EGFR and neoplasm: We, therefore, recommend the need for more detailed examination of both the primary tumours and corresponding metastasis to accurately determine the level, cellular location, and intensity of the therapeutic target, which is the EGFR protein as well as RAS status, when considering the use of EGFR targeted therapies in mCRC.